Home › Companies › PLIANT THERAPEUTICS INC. › 2024-2025

PLIANT THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and PLIANT THERAPEUTICS INC.’s Form 8-K, filed 2025-06-09 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
147Asset managers
851Fund votes
2025-06-05Meeting date

Proxy season: 2023-2024 2024-2025

Explore PLIANT THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by PLIANT THERAPEUTICS INC.

These tallies are PLIANT THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-09 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PLIANT THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-05
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: John Curnutte, M.D., Ph.D.	34,534,316	--	--	5,351,841	--	Majority: yes
Elect Director: Katharine Knobil, M.D.	26,681,127	--	--	13,205,030	--	Majority: yes
Elect Director: Thomas McCourt	31,557,399	--	--	8,328,758	--	Majority: yes
Proposal 1: "), (ii) to approve, by non-binding advisory vote, the resolution approving the compensation of the Company's named executive officers ("Proposal No. 2"), (iii) to approve an amendment to the Company's Amended and Restated Certificate of Incorporat	30,037,373	8,937,835	910,949	--	--	Majority: yes

Source: PLIANT THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-09 — read the filing on EDGAR.

How asset managers voted at the PLIANT THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 147 asset managers that disclosed a PLIANT THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of PLIANT THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, by non-binding advisory vote, the resolution approving Named Executive Officers compensation.

SECTION 14A SAY-ON-PAY VOTES

74% fund support · no official result

FOR 72%AGAINST 26%

The 142 asset managers below cast 74% of the shares they voted on this item FOR (27,515,352 for, 9,746,590 against).

FOR: 27,515,352 (72.2%)AGAINST: 9,746,590 (25.6%)ABSTAIN: 850,000 (2.2%)NOT VOTED: 4,500 (0.0%)

Largest asset managers voting on “To approve, by non-binding advisory vote, the resolution approving Named Executive Officers compensation.” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Deep Track Capital, LP	5,399,681	0	0	For
BlackRock	4,762,310	880	0	For
Vanguard	3,526,563	23,162	0	For
Blue Owl Capital Holdings LP	2,964,337	0	0	For
Cormorant Asset Management, LP	2,367,310	0	0	For
Madison Avenue Partners, LP	0	2,215,765	0	Against
Woodline Partners LP	2,030,963	0	0	For
Redmile Group, LLC	1,927,988	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,336,128	0	0	For
Fidelity	1,242,479	0	0	For
BESSEMER TRUST Co NATIONAL ASSOCIATION	0	1,059,466	0	Against
State Street	976,919	22,632	0	For
GREAT POINT PARTNERS LLC	0	0	850,000	Abstain
Charles Schwab	0	781,446	0	Against
Bessemer Trust CO of Delaware, N.A.	0	536,888	0	Against
BESSEMER TRUST CO	0	532,118	0	Against
BESSEMER TRUST Co OF FLORIDA	0	532,118	0	Against
Bessemer Trust Co of Nevada, National Association	0	532,118	0	Against
Rock Springs Capital Management LP	0	346,703	0	Against
Northern Trust	289,197	4,991	0	For
ArrowMark Colorado Holdings LLC	0	281,189	0	Against
Dimensional	0	258,220	0	Against
Graham Capital Management, L.P.	0	231,343	0	Against
MELLON INVESTMENTS Corp	208,147	0	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	190,094	0	Against

Showing the 25 largest of 142 asset managers. See all 142 in the interactive database.

2. To elect three class II directors named in the proxy statement to our Board of Directors: John Curnutte, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 34,534,316WITHHELD: 5,351,841

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: John Curnutte, M.D., Ph.D.”): 34,534,316 for, 5,351,841 withheld, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,386,278 outstanding shares: 56% for, 9% withheld (65% of the company cast a for/withheld vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (8,390,606 for, 0 against).

FOR 94%

FOR: 8,390,606 (94.0%)ABSTAIN: 539,836 (6.0%)

Largest asset managers voting on “To elect three class II directors named in the proxy statement to our Board of Directors: John Curnutte, M.D.,” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,365,967	0	For
BlackRock	2,854,683	0	For
Fidelity	1,210,262	12,081	For
Charles Schwab	390,723	0	For
Dimensional	0	207,392	Abstain
TIAA	0	154,332	Abstain
Equitable	92,481	58,180	For
QUANTITATIVE MASTER SERIES LLC	94,130	0	For
Lincoln Financial	34,937	44,809	Abstain
Invesco	36,203	0	For
Northern Trust	35,294	0	For
AIG/SunAmerica	33,988	0	For
Global X	33,545	0	For
Pacific Life	29,030	0	For
T. Rowe Price	0	27,338	Abstain
Bridge Builder Trust	25,462	0	For
John Hancock	21,653	1,976	For
CLEARWATER INVESTMENT TRUST	19,488	0	For
Goldman Sachs	18,363	0	For
Voya	16,319	0	For
JPMorgan	15,922	0	For
ProShares	14,009	0	For
SEI	11,200	0	For
Jackson National	0	9,535	Abstain
DWS	8,498	0	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

3. To elect three class II directors named in the proxy statement to our Board of Directors: Katharine Knobil, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%WITHHELD 33%

FOR: 26,681,127WITHHELD: 13,205,030

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Katharine Knobil, M.D.”): 26,681,127 for, 13,205,030 withheld, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,386,278 outstanding shares: 43% for, 22% withheld (65% of the company cast a for/withheld vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (5,080,801 for, 0 against).

FOR 57%ABSTAIN 43%

FOR: 5,080,801 (56.9%)ABSTAIN: 3,849,641 (43.1%)

Largest asset managers voting on “To elect three class II directors named in the proxy statement to our Board of Directors: Katharine Knobil, M.” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,365,967	0	For
BlackRock	0	2,854,683	Abstain
Fidelity	1,188,301	34,042	For
Charles Schwab	390,723	0	For
Dimensional	0	207,392	Abstain
TIAA	0	154,332	Abstain
Equitable	0	150,661	Abstain
QUANTITATIVE MASTER SERIES LLC	0	94,130	Abstain
Lincoln Financial	42,300	37,446	For
Invesco	0	36,203	Abstain
Northern Trust	0	35,294	Abstain
AIG/SunAmerica	0	33,988	Abstain
Global X	33,545	0	For
Pacific Life	0	29,030	Abstain
T. Rowe Price	0	27,338	Abstain
Bridge Builder Trust	0	25,462	Abstain
John Hancock	0	23,629	Abstain
CLEARWATER INVESTMENT TRUST	19,488	0	For
Goldman Sachs	0	18,363	Abstain
Voya	0	16,319	Abstain
JPMorgan	15,922	0	For
ProShares	0	14,009	Abstain
SEI	11,200	0	For
Jackson National	0	9,535	Abstain
DWS	0	8,498	Abstain

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

4. To elect three class II directors named in the proxy statement to our Board of Directors: Thomas McCourt

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD 21%

FOR: 31,557,399WITHHELD: 8,328,758

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Thomas McCourt”): 31,557,399 for, 8,328,758 withheld, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 61,386,278 outstanding shares: 51.4% for, 14% withheld (65% of the company cast a for/withheld vote).

The 39 asset managers below cast 100% of the shares they voted on this item FOR (7,895,409 for, 0 against).

FOR 88%12%

FOR: 7,895,409 (88.4%)ABSTAIN: 1,035,033 (11.6%)

Largest asset managers voting on “To elect three class II directors named in the proxy statement to our Board of Directors: Thomas McCourt” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,365,967	0	For
BlackRock	2,854,683	0	For
Fidelity	1,210,262	12,081	For
Charles Schwab	0	390,723	Abstain
Dimensional	0	207,392	Abstain
TIAA	0	154,332	Abstain
Equitable	92,481	58,180	For
QUANTITATIVE MASTER SERIES LLC	94,130	0	For
Lincoln Financial	42,300	37,446	For
Invesco	36,203	0	For
Northern Trust	35,294	0	For
AIG/SunAmerica	0	33,988	Abstain
Global X	33,545	0	For
Pacific Life	29,030	0	For
T. Rowe Price	0	27,338	Abstain
Bridge Builder Trust	25,462	0	For
John Hancock	0	23,629	Abstain
CLEARWATER INVESTMENT TRUST	19,488	0	For
Goldman Sachs	0	18,363	Abstain
Voya	16,319	0	For
JPMorgan	15,922	0	For
ProShares	0	14,009	Abstain
SEI	11,200	0	For
Jackson National	0	9,535	Abstain
DWS	0	8,498	Abstain

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

5. TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO LIMIT THE LIABILITY OF CERTAIN OFFICERS OF PLIANT THERAPEUTICS, INC. AS PERMITTED BY DELAWARE LAW.

CORPORATE GOVERNANCE

99.0% fund support · no official result

FOR 99.0%

The 39 asset managers below cast 99.0% of the shares they voted on this item FOR (8,846,038 for, 84,404 against).

FOR: 8,846,038 (99.1%)AGAINST: 84,404 (0.9%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO LIMIT THE LIABILITY OF CER” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	3,365,967	0	For
BlackRock	2,854,683	0	For
Fidelity	1,222,343	0	For
Charles Schwab	390,723	0	For
Dimensional	207,392	0	For
TIAA	154,332	0	For
Equitable	150,661	0	For
QUANTITATIVE MASTER SERIES LLC	94,130	0	For
Lincoln Financial	79,746	0	For
Invesco	36,203	0	For
Northern Trust	35,294	0	For
AIG/SunAmerica	33,988	0	For
Global X	0	33,545	Against
Pacific Life	29,030	0	For
T. Rowe Price	27,338	0	For
Bridge Builder Trust	25,462	0	For
John Hancock	23,629	0	For
CLEARWATER INVESTMENT TRUST	0	19,488	Against
Goldman Sachs	18,363	0	For
Voya	16,319	0	For
JPMorgan	0	15,922	Against
ProShares	14,009	0	For
SEI	0	11,200	Against
Jackson National	9,535	0	For
DWS	8,498	0	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

6. TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 39 asset managers below cast 99.9% of the shares they voted on this item FOR (8,930,208 for, 234 against).

FOR: 8,930,208 (100.0%)AGAINST: 234 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR TH” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Vanguard	3,365,967	For
BlackRock	2,854,683	For
Fidelity	1,222,343	For
Charles Schwab	390,723	For
Dimensional	207,392	For
TIAA	154,332	For
Equitable	150,661	For
QUANTITATIVE MASTER SERIES LLC	94,130	For
Lincoln Financial	79,746	For
Invesco	36,203	For
Northern Trust	35,294	For
AIG/SunAmerica	33,988	For
Global X	33,545	For
Pacific Life	29,030	For
T. Rowe Price	27,338	For
Bridge Builder Trust	25,462	For
John Hancock	23,629	For
CLEARWATER INVESTMENT TRUST	19,488	For
Goldman Sachs	18,363	For
Voya	16,319	For
JPMorgan	15,922	For
ProShares	14,009	For
SEI	11,200	For
Jackson National	9,535	For
DWS	8,498	For

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

46.3% fund support · no official result

FOR 46.3%AGAINST 53.7%

The 3 asset managers below cast 46.3% of the shares they voted on this item FOR (43,541 for, 50,570 against).

FOR: 43,541 (46.3%)AGAINST: 50,570 (53.7%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
JPMorgan	43,541	0	For
ALGERT GLOBAL LLC	0	42,814	Against
Desjardins Global Asset Management Inc.	0	7,756	Against

8. To approve by non-binding advisory vote the resolution approving Named Executive Officer compensation

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

99.0% fund support · no official result

FOR 99.0%

The 2 asset managers below cast 99.0% of the shares they voted on this item FOR (2,132,867 for, 20,834 against).

FOR: 2,132,867 (99.0%)AGAINST: 20,834 (1.0%)

Largest asset managers voting on “To approve by non-binding advisory vote the resolution approving Named Executive Officer compensation” at PLIANT THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
TRV GP IV, LLC	2,132,867	0	0	0	For
Rhumbline	0	20,834	0	0	Against

Largest PLIANT THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of PLIANT THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 61,386,278 shares outstanding at the time of that meeting.

Top PLIANT THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Deep Track Capital, LP	8.80%
2	BlackRock	7.76%
3	Vanguard	5.78%
4	Blue Owl Capital Holdings LP	4.83%
5	Cormorant Asset Management, LP	3.86%
6	Madison Avenue Partners, LP	3.61%
7	Woodline Partners LP	3.31%
8	Redmile Group, LLC	3.14%
9	GEODE CAPITAL MANAGEMENT, LLC	2.18%
10	Fidelity	2.02%

Reported PLIANT THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

PLIANT THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Tang Capital Management LLC	9.54%	DEF14A
Deep Track Capital, LP	9.37%	DEF14A
BlackRock	8.54%	13F
Vanguard Group	5.43%	13F
Paradigm Biocapital Advisors LP	4.98%	DEF14A
Morgan Stanley	4.97%	13F
Kenneth Griffin	4.96%	13G
Redmile Group, LLC	4.72%	13G
Bernard Coulie, M.D., Ph.D., M.B.A.	3.31%	DEF14A
Woodline Partners LP	3.30%	13G

Percentages above are of 61,386,278 shares outstanding, as reported by PLIANT THERAPEUTICS INC. on its Form 10-Q dated 2025-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PLIANT THERAPEUTICS INC.’s 10-Q dated 2025-05-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At PLIANT THERAPEUTICS INC.'s shareholder meeting held 2025-06-05, in the 2024-2025 proxy season, 147 asset managers reported how they voted in their SEC Form N-PX filings, covering 851 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. PLIANT THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, by non-binding advisory vote, the resolution approving Named Executive Officers… — the reporting funds cast 74% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

PLIANT THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).